Yavuz Özışık
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Cancer Research top 10%
- Molecular Biology
- Pathology and Forensic Medicine top 10%
- Co-authors
- Kadri AltundağAurelia M. MeloniAvery A. SandbergUrvashi SurtiTaner BabacanMutlu HayranSercan Aksoyİbrahim Güllü
- Topics
- Cancer Treatment and Pharmacology (14 papers)Breast Cancer Treatment Studies (14 papers)HER2/EGFR in Cancer Research (10 papers)
- Partner nations
- TürkiyeUnited StatesCanada
In The Last Decade
Yavuz Özışık
55 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 92
- Oncology 615
- Pulmonary and Respiratory Medicine 299
- Cancer Research 278
- Molecular Biology 214
- Pathology and Forensic Medicine 155
Countries citing papers authored by Yavuz Özışık
This map shows the geographic impact of Yavuz Özışık's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yavuz Özışık with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yavuz Özışık more than expected).
Fields of papers citing papers by Yavuz Özışık
This network shows the impact of papers produced by Yavuz Özışık. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yavuz Özışık. The network helps show where Yavuz Özışık may publish in the future.
Co-authorship network of co-authors of Yavuz Özışık
This figure shows the co-authorship network connecting the top 25 collaborators of Yavuz Özışık. A scholar is included among the top collaborators of Yavuz Özışık based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yavuz Özışık. Yavuz Özışık is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. | 0 |
| 2 | A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer. | 5 |
| 3 | 40 | |
| 4 | 18 | |
| 5 | 5 | |
| 6 | 130 | |
| 7 | 43 | |
| 8 | 10 | |
| 9 | 8 | |
| 10 | 6 | |
| 11 | 15 | |
| 12 | 25 | |
| 13 | 18 | |
| 14 | 37 | |
| 15 | 16 | |
| 16 | 21 | |
| 17 | 17 | |
| 18 | 56 | |
| 19 | 28 | |
| 20 | 13 |
About Yavuz Özışık
Yavuz Özışık is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 56 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (10 papers). The work is most often cited by research in Oncology (615 citations), Cancer Research (278 citations) and Obstetrics and Gynecology (127 citations). Yavuz Özışık has collaborated with scholars based in Türkiye, United States and Canada. Frequent co-authors include Kadri Altundağ, Aurelia M. Meloni, Avery A. Sandberg, Urvashi Surti, Taner Babacan, Mutlu Hayran, Sercan Aksoy, İbrahim Güllü, Ömer Dızdar and İbrahim Petekkaya. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Journal of the American Academy of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.